According to findings from the TALAPRO-2 study, the combination led to significant and meaningful improvements in overall survival vs enzalutamide monotherapy.

Eric Cheung, DO, Targeted Oncology’s second 2024 Oncology Icon, discussed his journey in oncology, advances in treatment, and his patient-centered approach to care.

The FDA has approved the WATER IV PCa trial, which will compare the safety and efficacy of Aquablation therapy to radical prostatectomy in patients with localized prostate cancer.

The first patient with advanced gastric and gastroesophageal cancer has been dosed in a trial combining PT886 with pembrolizumab.

Samer A. Al'Hadidi, MD, MS, reviewed the benefits of cilta-cel in the subgroup analysis of CARTITUDE-4 in patients with relapsed/refractory multiple myeloma and functional high risk, bridging to cilta-cel, and time to treatment in the second article of a 2-part series.

Yufei Liu, MD, PhD, discussed the importance of careful data interpretation to accurately assess the efficacy of new treatment options in oncology.

The sponsor is preparing a phase 2 study to evaluate namodenoson in this patient population.

Jacob E. Berchuck, MD, discussed research behind using a blood-based liquid biopsy in prostate cancer and findings presented at the 2024 ESMO Congress.

During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on how recent trial data and sites of metastasis affect treatment of favorable-risk metastatic clear cell renal cell carcinoma in the second article of a 2-part series.

The SunRISe-2 trial evaluating TAR-200 combined with cetrelimab vs chemoradiation in muscle-invasive bladder cancer has been discontinued.

The first patient in a phase 1/2 trial investigating a novel agent for the treatment of non–small cell lung cancer has been dosed.

The FDA has granted VLS-1488 fast track designation in patients with platinum-resistant high-grade serous ovarian cancer.

The KEYNOTE-689 study evaluating pembrolizumab in this patient population met its primary end point of event-free survival.

Ana Baramidze, MD, PhD, discussed 5-year follow-up results from the EMPOWER-Lung study evaluating cemiplimab vs chemotherapy in advanced first-line non–small cell lung cancer.

A new study suggests that patients with multiple myeloma who achieve sustained MRD-negativity for at least three years may be able to discontinue maintenance therapy without compromising their long-term outcomes.

In an interview with Targeted Oncology, Rupesh Kotecha, MD, discussed a machine learning tool designed to predict local failure after stereotactic radiosurgery for brain metastases.

Test your knowledge on the current pulse of oncology including FDA updates and breaking data with our Targeted Pulse Quiz.

Durcabtagene autoleucel shows high response rates in R/R multiple myeloma; olomorasib plus pembrolizumab demonstrates efficacy in KRAS G12C-mutated NSCLC; and the combination of talquetamab, daratumumab, and pomalidomide achieves durable responses. We also cover the FDA’s ODAC vote against checkpoint inhibitors for esophageal cancer.

The final analysis of the phase 3 PANTHER study confirmed survival benefits for patients receiving dose-dense vs standard chemotherapy.

HBI0101, an academically sourced CAR T-cell therapy, demonstrated a high objective response rate and manageable safety in patients with relapsed/refractory multiple myeloma.

The noninvasive test provides a beneficial screening tool for patients 45 and older at average risk for colorectal cancer.

M. Michele Blackwood, MD, FACS, provided an overview of the significant advancements with personalized medicine with genomic testing in the breast cancer space.

For Breast Cancer Awareness Month, Oranus Mohammadi, MD, discussed the remarkable progress made in improving survival rates for patients with breast cancer.

The 2024 International Myeloma Society Annual Meeting was a groundbreaking event that showcased the latest advancements in multiple myeloma research and treatment.

The FDA has approved nivolumab plus chemotherapy as a neoadjuvant treatment for operable stage IIA to IIIB non–small cell lung cancer, based on data from the phase 3 CheckMate 77T trial.